NLM Digital Collections

Search

Search Constraints

Start Over You searched for: Subjects United+States Remove constraint Subjects: United+States

Search Results

8441. Hematologic malignancies: regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment

8442. REMS: FDA's application of statutory factors in determining when a REMS is necessary

8443. Extending expiration dates of doxycycline tablets and capsules in strategic stockpiles: guidance for government public health and emergency response stakeholders

8444. Class II special controls guideline: in vitro diagnostic devices for Bacillus spp. detection : guideline for industry and Food and Drug Administration staff

8445. 30-Day notices, 135-day premarket approval (PMA) supplements and 75-day humanitarian device exemption (HDE) supplements for manufacturing method or process changes: guidance for industry and Food and Drug Administration staff

8446. Unique device identification: convenience kits : guidance for industry and Food and Drug Administration staff

8447. Requests for feedback and meetings for medical device submissions: the Q-Submission Program : guidance for industry and Food and Drug Administration staff

8448. Utilizing animal studies to evaluate organ preservation devices: guidance for industry and Food and Drug Administration staff

8449. Medical x-ray imaging devices conformance: guidance for industry and Food and Drug Administration staff

8450. Policy clarification for certain fluoroscopic equipment requirements: guidance for industry and Food and Drug Administration staff